Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

By S. Marso, S. Bain, A. Consoli, F. Eliaschewitz, E. Jódar, Lawrence A Leiter, I. Lingvay, J. Rosenstock, J. Seufert, M. Warren and 5 more. New England Journal of Medicine, 2016

5,194 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Surgery

View Paper: https://www.semanticscholar.org/paper/883e9785193db22caecc913601d42f080b3b93be

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. J. Meier
2. M. Nauck
3. D. J. Drucker
4. L. Knudsen
5. Michael J. Pencina
6. F. Reimann
7. F. Gribble
8. John B. Buse

In Surgery

1. J. Meier
2. M. Nauck
3. D. J. Drucker
4. L. Knudsen
5. Michael J. Pencina
6. F. Reimann
7. P. Rossing
8. F. Gribble

Citations in the corpus

• A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association (2023, background): “165,205 In individuals with diabetes and ASCVD, the approach to prioritizing selection of SGLT2 inhibitors versus GLP-1RAs is unclear because these therapies have not been directly compared in clinical trials.”
• Vascular Inflammation and Oxidative Stress: Major Triggers for Cardiovascular Disease (2019, background): “95; p < 0 001 for noninferiority) [233, 234].”
• Glucagon-like peptide 1 (GLP-1) (2019, background): “In patients with type 2 diabetes, semaglutide also reduces the risk for an adverse cardiovascular event, with decreased rates of MACE (Major Adverse Cardiovascular Events, comprising cardiovascular death, nonfatal myocardial infarction and stroke) [899].”
• Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024, background): “467 Under hyperglycemic conditions, GLP-1RAs regulate hypertension by inhibiting carotid body function.”